-
8641
Distribution of anti-nuclear antibodies (ANA), anti-dsdna and extractable nuclear antigens (ENA) antibodies among apparently healthy malay women and determination of ana cutofft...
Published 2013“…Some autoantibodies play a very important role in the pathogenesis, diagnosis and prognosis of autoimmune diseases including antinuclear antibodies (ANA), antidsDNA and ENA antibodies. …”
Get full text
Monograph -
8642
Differences in children and adolescents with SARS-CoV-2 infection: a cohort study in a Brazilian tertiary referral hospital
Published 2021-11-01“…RESULTS: The frequencies of sore throat, anosmia, dysgeusia, headache, myalgia, nausea, lymphopenia, pre-existing chronic conditions, immunosuppressive conditions, and autoimmune diseases were significantly reduced in children and adolescents (p<0.05). …”
Get full text
Article -
8643
Comparative effects of human-equivalent low, moderate, and high dose oral prednisone intake on autoimmunity and glucocorticoid-related toxicity in a murine model of environmental-t...
Published 2022-10-01“…Autoimmune diseases can be triggered by environmental toxicants such as crystalline silica dust (cSiO2). …”
Get full text
Article -
8644
Interferon response and profiling of interferon response genes in peripheral blood of vaccine-naive COVID-19 patients
Published 2024-01-01“…Expression of interferon-stimulated genes (ISGs) in peripheral blood (better known as interferon score) has been a well-established bioassay marker of systemic IFN responses in autoimmune diseases. Therefore, with archival samples of a cohort of COVID-19 patients collected before the availability of vaccination, we aimed to better understand this innate immune response by studying the IFN score and related ISGs expression in bulk and single cell RNAs sequencing expression datasets.MethodsIn this study, we recruited 105 patients with COVID-19 and 30 healthy controls in Hong Kong. …”
Get full text
Article -
8645
Actualización sobre los medicamentos biocomparables en la enfermedad inflamatoria intestinal: posición y recomendación en México
Published 2018-10-01“…Clinical trials have shown that the infliximab biosimilar, CT-P13, and the candidates for the adalimumab biosimilars, ABP 501 and ZRC 3197, are not significantly different, with respect to efficacy and safety, from the originator drugs in patients with other autoimmune diseases. However, controversy has arisen over the use of biosimilars in inflammatory bowel disease, due to the incipient evidence not only in patients with no previous biotechnology treatment, but also in patients in remission, that could be switched to a biosimilar for non-medical reasons.The present review is the first critical analysis by different specialists in the area of gastroenterology on the use of biosimilars in inflammatory bowel disease, the evidence on interchangeability, the extrapolation of indications, efficacy, safety, immunogenicity, and the clinical impact of the Mexican health regulations. …”
Get full text
Article -
8646
The Autoinflammatory Diseases Alliance Registry of monogenic autoinflammatory diseases
Published 2022-09-01Get full text
Article -
8647
Negative costimulatory molecule B7-H4 mediates protective effect of mesenchymal stem cells on experimental autoimmune encephalomyelitis
Published 2022-12-01“…These findings may provide a new avenue and target molecule in MSC-based therapy for autoimmune diseases in the central nervous system, such as multiple sclerosis and neuromyelitis optica spectrum disorder.…”
Get full text
Article -
8648
miR-146a in Myasthenia Gravis Thymus Bridges Innate Immunity With Autoimmunity and Is Linked to Therapeutic Effects of Corticosteroids
Published 2020-03-01“…Considerable evidence indicate that uncontrolled TLR activation and chronic inflammation significantly contribute to hyperplastic changes and germinal center (GC) formation in the MG thymus, ultimately leading to autoantibody production and autoimmunity. miR-146a is a key modulator of innate immunity, whose dysregulation has been associated with autoimmune diseases. It acts as inhibitor of TLR pathways, mainly by targeting the nuclear factor kappa B (NF-κB) signaling transducers, interleukin 1 receptor associated kinase 1 (IRAK1) and tumor necrosis factor (TNF) receptor associated factor 6 (TRAF6); miR-146a is also able to target c-REL, inducible T-cell costimulator (ICOS), and Fas cell surface death receptor (FAS), known to regulate B-cell function and GC response. …”
Get full text
Article -
8649
SURGERY FOR PRIMARY DIFFUSE LARGE B-CELL-LYMPHOMA OF THE CENTRAL NERVOUS SYSTEM - A CASE REPORT
Published 2023-10-01“…They are often associated with EBV or HIV infection and also affect transplant patients or those with autoimmune diseases, as in the reported case. They usually do not present B symptoms as manifestations, but rather neurological symptoms such as speech and/or motor disorders, mental confusion, seizures, and change on consciousness level. …”
Get full text
Article -
8650
MOLECULAR GENETIC TESTING OF ACCP-POSITIVE PATIENTS WITH RHEUMATOID ARTHRITIS AND HIGH INFLAMMATORY DISEASE ACTIVITY (A REMARCA STUDY)
Published 2018-03-01“…A molecular genetic study enrolled 146 aCCP-positive patients from the REMARCA program and a control group of 314 healthy blood donors without autoimmune diseases and their presence in the history, who were matched with the study group for gender and sex. …”
Get full text
Article -
8651
-
8652
[Artículo traducido] Baja dosis de rituximab para penfigoide ampolloso. Protocolo y experiencia de un único centro
Published 2023-01-01“…Abstract: Background: Low-dose rituximab is a protocol used in several autoimmune diseases, that has also shown to be effective and safe in pemphigus vulgaris. …”
Get full text
Article -
8653
Features of renal dysfunction in children with systemic lupus erythematosus and juvenile idiopathic arthritis
Published 2017-09-01“…Background. In systemic autoimmune diseases of the connective tissue, kidney damage in some cases is a syndrome of the disease, and in others, it is a consequence of the underlying process. …”
Get full text
Article -
8654
Immunological markers for predicting the response to immunotherapy in non-small cell lung cancer
Published 2022-06-01“…All patients from 2 groups did not have autoimmune diseases before starting treatment. The determination of autoantibodies, β-2-microglobulin, neopterin, interleukin 6, interleukin 18 and the allelic variant of HLA-DRB1 in patients in the Group 1 was carried out 2 months after the start of therapy, and in the Group 2 – before the start of the next chemotherapy cycle.Results. …”
Get full text
Article -
8655
Long-term impact of pre-incision antibiotics on children born by caesarean section: a longitudinal study based on UK electronic health records
Published 2022-06-01“…Additional secondary outcomes, including other allergy-related conditions, autoimmune diseases, infections, other immune system-related diseases and neurodevelopmental conditions, were also assessed. …”
Get full text
Article -
8656
-
8657
-
8658
Polyphenols and Their Impact on the Prevention of Neurodegenerative Diseases and Development
Published 2023-08-01“…Polyphenols act on the brain endothelial cells and improve the BBB’s integrity and reduce inflammation, thus protecting the brain from additional injury during stroke or autoimmune diseases. Polyphenolic compounds are capable of lowering blood pressure and improving cerebral blood flow. …”
Get full text
Article -
8659
Regulation of CD47 expression on CD14+ monocytes by interferon-α in PBC patients
Published 2023-12-01“…CD47/signal-regulatory protein alpha (SIRPα) is closely related to developing autoimmune diseases by promoting inflammatory response. …”
Get full text
Article -
8660
Low-Dose Rituximab for Bullous Pemphigoid. Protocol and Single-Center Experience
Published 2023-01-01“…Background: Low-dose rituximab is a protocol used in several autoimmune diseases, that has also shown to be effective and safe in pemphigus vulgaris. …”
Get full text
Article